GMT Capital Corp Has $23.12 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• GMT Capital Corp reduced its stake in Lantheus Holdings, Inc. by 48.2%, now owning 236,900 shares valued at approximately $23.12 million.
• Lantheus' earnings report revealed an EPS of $1.57, missing estimates by $0.08 and marking a 4.1% revenue decline year-over-year.
• Insiders sold over 6.8 million shares of Lantheus stock worth around $384.43 million in the last quarter.

GMT Capital Corp trimmed its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 48.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 236,900 shares of the medical equipment provider's stock after selling 220,600 shares during the period. Lantheus comprises approximately 1.2% of GMT Capital Corp's investment portfolio, making the stock its 22nd biggest position. GMT Capital Corp owned approximately 0.35% of Lantheus worth $23,121,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC increased its holdings in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the period. Farallon Capital Management LLC increased its holdings in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. Westfield Capital Management Co. LP increased its holdings in Lantheus by 2.2% in the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider's stock valued at $155,101,000 after purchasing an additional 34,052 shares during the period. Dimensional Fund Advisors LP increased its holdings in Lantheus by 2.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider's stock valued at $134,534,000 after purchasing an additional 31,454 shares during the period. Finally, Silvercrest Asset Management Group LLC increased its holdings in Lantheus by 39.1% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock valued at $87,124,000 after purchasing an additional 273,838 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Down 1.1%

LNTH traded down $0.60 during trading on Monday, reaching $54.90. 1,028,454 shares of the stock traded hands, compared to its average volume of 2,626,054. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $3.73 billion, a PE ratio of 14.60 and a beta of 0.15. The stock's 50-day moving average is $68.68 and its 200 day moving average is $83.02. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The company had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.Lantheus's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period last year, the company earned $1.80 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on LNTH shares. Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. JMP Securities decreased their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $105.50.

Insider Activity

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 2.00% of the stock is currently owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.